SUNSHINE PHARMA (06887) surged more than 6% during the afternoon session. As of the time of writing, the stock was up 6.55%, trading at HK$46.2, with a turnover of HK$30.6289 million. On January 16, the company's self-developed Class 1 innovative drug, Ologliflozin Capsules, received approval from the National Medical Products Administration for market launch. The drug is indicated for improving glycemic control in adult patients with type 2 diabetes, either as a monotherapy or in combination with metformin. A representative from SUNSHINE PHARMA stated that the approval of Ologliflozin represents a solid step forward in the company's long-term management strategy for chronic diseases. Notably, SUNSHINE PHARMA recently announced that the Group is continuously deepening its AI strategic layout by launching an AI-powered R&D platform targeting the PROTAC mechanism. This platform achieves a "dry-wet closed loop" from the data foundation, with both data scale and structural granularity significantly leading existing public databases. It provides a comprehensive and systematic data foundation for AI-driven rational design of PROTACs, accelerating the rational design and clinical translation of PROTAC lead compounds.